Wednesday, May 5, 2021
PARTICIPANTS LOG IN / NETWORKING ACTIVITIES
8:30 - 9:45  
Introduction
9:45 - 10:15

Welcome and Introduction to the Programme

Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada

William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada


Remembering Henry Lynch

Lisa Madlensky, PhD, CGC, Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA, USA

Steven Narod, MD, FRCPC, FRSC, Canada Research Chair in Breast Cancer, Women’s College Research Institute, Toronto, ON, Canada



SESSION 4:
Special Round Table: Population-based approaches to genetic testing and risk assessment – Beyond the current models
10:15 - 11:45

MODERATORS: Lawrence Brody, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA; and Clare Turnbull, MD, PhD, MFPH, Institute of Cancer Research, London, UK

INTRO, OVERVIEW, CONSIDERATIONS

Paul Pharoah, BM, BCh, PhD, University of Cambridge, Cambridge, UK

POPULATION TESTING

Integrated service provider program: the Geisinger experience

Adam Buchanan, MS, MPH, LGC, Genomic Medicine Institute, Geisinger Health System, Danville, PA, USA

National approaches: USA and beyond

Stephen Chanock¸ MD, National Cancer Institute, Rockville, MD, USA

Founder testing – the Israel approach: Is it generalizable?

Ephrat Levy-Lahad, MD, Shaare Zedek Medical Center, Jerusalem, Israel

BREAK
INDUSTRY-SPONSORED SYMPOSIUM
11:45 - 13:30  
SESSION 5:
Early diagnosis of breast and prostate cancer in BRCA1 or BRCA2 heterozygotes
13:30 - 14:30

CHAIR: Jeffrey Weitzel, MD, City of Hope National Medical Center, Duarte, CA, USA

13:30 - 13:50

MRI and the early diagnosis of breast cancer in BRCA1 and BRCA2 heterozygotes

Steven Narod, MD, FRCPC, FRSC, Canada Research Chair in Breast Cancer, Women’s College Research Institute, Toronto, ON, Canada

13:50 - 14:00

Question period

14:00 - 14:20

Prostate cancer in men with BRCA1 or BRCA2 pathogenic variants - the IMPACT STUDY

Elena Castro, MD, PhD, CNIO-IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Malaga (IBIMA), Málaga, Spain

14:20 - 14:30

Question period

BREAK
14:30 - 14:45  
SESSION 6:
Genetic counselling – New challenges
14:45 - 16:15

CHAIR: Antonis Antoniou PhD, University of Cambridge, Cambridge, UK

14:45 - 15:05

Genetic Counseling for a general population: lessons learned

Kelly Tangney, MS, LCGC, Color Health, Inc., Burlingame, CA, USA

15:05 - 15:25

A practical approach to handling direct-to-consumer data

Lisa Madlensky, PhD, CGC, Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA, USA

15:25 - 15:35

Proffered paper 1 (S6-PP1)
A Gynecologic Oncologist-led Mainstreaming Approach of Germline Genetic Testing for Patients with Ovarian Cancer; First Experiences of Healthcare Professionals and Patients

Kyra Bokkers, MD / PhD Student, University Medical Center Utrecht, Utrecht, The Netherlands

15:35 - 15:45

Proffered paper 2 (S6-PP2)
Large Scale Group Genetic Counselling: A Novel Service Delivery Model in British Columbia

Zoe Lohn, MSc., BC Cancer, Vancouver, BC, Canada

15:45 - 15:55

Proffered paper 3 (S6-PP3)
Genetic Cancer Risk Assessment Outcomes for Latin American Participants in the GRACIAS (genetic risk assessment for cancer implementation and sustainment) study: Growing Reach, Cascade Testing, and Access to Risk Reduction Surgeries

Jeffrey Weitzel, MD, Duarte, CA, USA

15:55 - 16:15

Question and discussion period (all speakers)

BREAK
16:15 - 16:45  
Wednesday
Special Interest Groups (SIGs)
16:45 - 17:45

Moderated one-hour interactive discussions with the aim of fostering bilateral knowledge transfer. Choice of the following 2 SIGs.

SIG 1:

Moderate risk genes – When and where are they useful?

In this session, the four experts will discuss the role of clinical testing for moderate risk breast and ovarian cancer susceptibility genes. They will review data on the cancer risks associated with pathogenic variants in each of the major moderate risk genes (e.g. ATM, BARD1, BRIP1, CHEK2, RAD51C, RAD51D) and will discuss emerging candidate genes. Models to assess risk will be discussed, as will counseling challenges. The pathology of tumors associated with pathogenic variants in these genes will be considered.

  • Paul James, MD, PhD, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (session lead)

  • Mark Robson, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

  • Lisa Madlensky, PhD, CGC, Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA, USA

  • Marjanka Schmidt, PhD, Netherlands Cancer Institute, Amsterdam, and Leiden University Medical Center, Leiden, The Netherlands

SIG 2:

Ethico-legal issues around usage of genomic data

Some of the issues that will be discussed in this interactive session include genetic counselling in the private direct to consumer testing era, patenting of genes and its influence on data sharing, secrecy vs open innovation, ethical aspects of large-scale genomic sequencing and genetic discrimination. Attendees will be encouraged to send in specific ethics questions in advance for discussion at the SIG.

  • Yann Joly, PhD, AdE McGill University, Montréal, QC, Canada (session lead)

  • Yvonne Bombard, PhD, BSc, St. Michael's Hospital, Toronto, ON, Canada

  • Nathalie Bolduc, MSc, Quebec Breast Cancer Foundation, Montréal, QC, Canada

  • Robert Cook-Deegan, MD, Arizona State University, Washington, DC, USA